Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study

医学 阿替唑单抗 贝伐单抗 临床终点 肝细胞癌 内科学 实体瘤疗效评价标准 肿瘤科 无进展生存期 临床研究阶段 阶段(地层学) 索拉非尼 外科 胃肠病学 癌症 临床试验 总体生存率 化疗 无容量 免疫疗法 古生物学 生物
作者
Masatoshi Kudo,Kazuomi Ueshima,Kaoru Tsuchiya,Tatsuya Yamashita,Shigeo Shimose,Kazushi Numata,Yuzo Kodama,Shinji Itoh,Yasuhito Tanaka,Hidekatsu Kuroda,Hiroshi Aikata,Atsushi Hiraoka,Michihisa Moriguchi,Ryosuke Tateishi,Sadahisa Ogasawara,Kouji Yamamoto,Masafumi Ikeda
出处
期刊:Liver cancer [Karger Publishers]
卷期号:15 (1): 104-116 被引量:17
标识
DOI:10.1159/000546899
摘要

Introduction: Intermediate-stage hepatocellular carcinoma (HCC) presents varying tumor burdens. For patients unsuitable for transcatheter arterial chemoembolization (TACE) due to high tumor burden, recent guidelines recommend systemic therapy. This study evaluates the efficacy and safety of atezolizumab plus bevacizumab for TACE-unsuitable patients with unresectable intermediate-stage HCC beyond up-to-seven criteria. Methods: This prospective, phase II, single-arm, non-blinded study enrolled TACE-naïve patients with unresectable intermediate-stage HCC beyond up-to-seven criteria, Child-Pugh A, no previous systemic therapy, and ECOG Performance Status score of 0–1 from 35 sites in Japan. Patients received atezolizumab 1,200 mg and bevacizumab 15 mg/kg every 3 weeks. The primary endpoint was the 6-month progression-free survival (PFS) rate by modified RECIST (mRECIST). Key secondary endpoints included the objective response rate (ORR) and safety. Exploratory endpoints examined individual changes in tumor size, comparison by inverse probability weighting (IPW) of data with retrospective historical data of TACE-treated patients, and conversion rate to a curative intent therapy. Results: In total, 74 patients were enrolled from December 2020 to September 2021 (median follow-up, 15.1 months). The 6-month PFS rate by mRECIST was 66.8% (90% CI: 56.8, 75.0), and the lower limit of the 90% CI exceeded the pre-specified threshold of 55%. ORR by mRECIST was 40.5%. After treatment with atezolizumab plus bevacizumab, 10 patients, including 5 patients who had a tumor burden beyond the up-to-11 criteria at baseline, were able to transition to curative intent therapy. PFS by mRECIST by IPW was 9.2 months with atezolizumab plus bevacizumab versus 5.7 months with TACE (hazard ratio 0.67, p = 0.029). Adverse events (AEs), mostly hypertension, proteinuria, and malaise, were common. AEs requiring corticosteroids occurred in 10 patients (13.5%). Conclusion: Atezolizumab plus bevacizumab appears beneficial as first-line treatment for TACE-unsuitable patients with unresectable intermediate-stage unresectable HCC beyond up-to-seven criteria. Future strategies utilizing multimodal approaches may further improve outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xxx完成签到,获得积分10
刚刚
阿飞发布了新的文献求助10
1秒前
李建杉发布了新的文献求助10
1秒前
屹男完成签到,获得积分10
1秒前
1秒前
科研小白完成签到,获得积分10
1秒前
还是你天天完成签到 ,获得积分10
1秒前
镜花水月完成签到,获得积分10
1秒前
鲸落发布了新的文献求助10
1秒前
1秒前
2秒前
小二郎的应助被niiiiii采纳,获得10
2秒前
2秒前
赘婿的应助被科研通管家采纳,获得20
2秒前
宋宋完成签到,获得积分10
3秒前
七七完成签到,获得积分10
3秒前
丘比特的应助被科研通管家采纳,获得10
3秒前
一切顺利tsy完成签到,获得积分10
3秒前
深情安青的应助被科研通管家采纳,获得10
3秒前
Ren完成签到,获得积分0
3秒前
Owen的应助被科研通管家采纳,获得20
3秒前
彭于彦祖的应助被博修采纳,获得30
3秒前
bkagyin的应助被科研通管家采纳,获得10
3秒前
wanci的应助被科研通管家采纳,获得10
3秒前
3秒前
亳亳发布了新的文献求助10
3秒前
思源的应助被科研通管家采纳,获得10
3秒前
3秒前
脑洞疼的应助被科研通管家采纳,获得10
4秒前
忐忑的琦完成签到,获得积分10
4秒前
科目三的应助被科研通管家采纳,获得10
4秒前
英姑的应助被科研通管家采纳,获得10
4秒前
里哈哈发布了新的文献求助10
4秒前
上官若男的应助被科研通管家采纳,获得10
4秒前
大模型的应助被科研通管家采纳,获得10
4秒前
Pan完成签到,获得积分10
4秒前
激动的雅琴完成签到 ,获得积分10
4秒前
汉堡包的应助被科研通管家采纳,获得10
4秒前
4秒前
共享精神的应助被科研通管家采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185